Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Review

Recent Advances in Antigen-Loaded Dendritic Cell-Based Strategies for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia

Willemijn van den Ancker1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Marvin M van Luijn1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Theresia M Westers1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Hetty J Bontkes1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Jurjen M Ruben1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
,
Tanja D de Gruijl1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected];2 Department of Medical Oncology, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
,
Gert J Ossenkoppele1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
&
Arjan A van de Loosdrecht1 VU Institute for Cancer & Immunology, Cancer Center Amsterdam, VU University Medical Center and Department of Hematology. Tel.: +31 20 444 7349 Fax: +31 20 444 [email protected]
 show all
Pages 69-83 | Published online: 17 Dec 2009

Bibliography

  • Provan D , SingerCRJ, BaglinT, LilleymanJ: Acute myeloblastic leukaemia (AML). In: Oxford Handbook of Clinical Haematology. Provan D, Singer CRJ, Baglin T, Lilleyman J (Eds). Oxford University Press, Oxford, UK, 149–157 (2004).
  • Ridgway D : The first 1000 dendritic cell vaccinees.Cancer Invest.21(6) , 873–886 (2003).
  • Banchereau J , PaluckaAK: Dendritic cells as therapeutic vaccines against cancer.Nat. Rev. Immunol.5(4) , 296–306 (2005).
  • Ballestrero A , BoyD, MoranE, CirmenaG, BrossartP, NencioniA: Immunotherapy with dendritic cells for cancer.Adv. Drug Deliv. Rev.60(2) , 173–183 (2008).
  • Rosenberg SA , YangJC, RestifoNP: Cancer immunotherapy: moving beyond current vaccines.Nat. Med.10(9) , 909–915 (2004).
  • Itoh K , YamadaA, MineT, NoguchiM: Recent advances in cancer vaccines: an overview.Jpn J. Clin. Oncol.39(2) , 73–80 (2009).
  • Figdor CG , de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med.10(5) , 475–480 (2004).
  • Small EJ , SchellhammerPF, HiganoCS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.J. Clin. Oncol.24(19) , 3089–3094 (2006).
  • Dunn GP , BruceAT, IkedaH, OldLJ, SchreiberRD: Cancer immunoediting: from immunosurveillance to tumor escape.Nat. Immunol.3(11) , 991–998 (2002).
  • Chamuleau ME , WestersTM, vanDL et al.: Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Haematologica94(4) , 496–506 (2009).
  • Koebel CM , VermiW, SwannJB et al.: Adaptive immunity maintains occult cancer in an equilibrium state.Nature450(7171) , 903–907 (2007).
  • Binder RJ , SrivastavaPK: Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells.Nat.Immunol.6(6) , 593–599 (2005).
  • Burgdorf S , KautzA, BohnertV, KnollePA, KurtsC: Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation.Science316(5824) , 612–616 (2007).
  • Pardoll DM : Spinning molecular immunology into successful immunotherapy.Nat. Rev. Immunol.2(4) , 227–238 (2002).
  • Padovan E , LandmannRM, De Libero G: How pattern recognition receptor triggering influences T cell responses: a new look into the system. Trends Immunol.28(7) , 308–314 (2007).
  • Schnare M , BartonGM, HoltAC, TakedaK, AkiraS, MedzhitovR: Toll-like receptors control activation of adaptive immune responses.Nat. Immunol.2(10) , 947–950 (2001).
  • West MA , WallinRP, MatthewsSP et al.: Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling.Science305(5687) , 1153–1157 (2004).
  • Greiner J , SchmittM, LiL et al.: Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches.Blood108(13) , 4109–4117 (2006).
  • Saudemont A , QuesnelB: In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.Blood104(7) , 2124–2133 (2004).
  • Van luijn M , ChamuleauME, ThompsonJA et al.: CLIP down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T cell responses.Haematologica (2009) DOI:10.3324/haematol.2009.010595.
  • Chamuleau ME , FellerN, KelderA, van de Loosdrecht AA, Ossenkoppele GJ: High CLIP (class II associated invariant chain peptide) expression on minimal residual disease cells is associated with high relapse rate in AML patients. Blood108 , 11 (2006) (Abstract).
  • Chamuleau ME , van de Loosdrecht AA, Hess CJ et al.: High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica93(12) , 1894–1898 (2008).
  • Bronte V , MocellinS: Suppressive influences in the immune response to cancer.J. Immunother.32(1) , 1–11 (2009).
  • Szczepanski MJ , SzajnikM, CzystowskaM et al.: Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.Clin. Cancer Res.15(10) , 3325–3332 (2009).
  • Jedema I , MeijP, SteeneveldE et al.: Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-γ secretion assay.Clin. Cancer Res.13(2 Pt 1) , 636–643 (2007).
  • O‘Neill DW , AdamsS, BhardwajN: Manipulating dendritic cell biology for the active immunotherapy of cancer.Blood104(8) , 2235–2246 (2004).
  • Andersen MH , SorensenRB, SchramaD, SvaneIM, BeckerJC, ThorSP: Cancer treatment: the combination of vaccination with other therapies.Cancer Immunol. Immunother.57(11) , 1735–1743 (2008).
  • Li L , ReinhardtP, SchmittA et al.: Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.Cancer Immunol. Immunother.54(7) , 685–693 (2005).
  • Roddie H , KlammerM, ThomasC et al.: Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.Br. J. Haematol.133(2) , 152–157 (2006).
  • Houtenbos I , WestersTM, OssenkoppeleGJ, van de Loosdrecht AA: Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology211(6–8) , 677–685 (2006).
  • Santegoets SJ , MastersonAJ, van der Sluis PC et al.: A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor. J. Leukoc. Biol.80(6) , 1337–1344 (2006).
  • Masterson AJ , SombroekCC, de Gruijl TD et al.: MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood100(2) , 701–703 (2002).
  • Santegoets SJ , van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD: Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J. Leukoc. Biol.84(6) , 1364–1373 (2008).
  • Rasaiyaah J , NoursadeghiM, KellamP, ChainB: Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line.Immunology127(3) , 429–441 (2009).
  • Lee JJ , ChoiBH, KangHK et al.: Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.Leuk. Res.32(11) , 1653–1660 (2008).
  • Lee JJ , NamCE, NamJH et al.: Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells.Leuk. Res.28(5) , 517–524 (2004).
  • van de Loosdrecht AA : The dendritic cell: the piano player in orchestrating the immune response in leukemia.Leuk. Lymphoma48(2) , 217–218 (2007).
  • Gong J , KoidoS, KatoY et al.: Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.Leuk. Res.28(12) , 1303–1312 (2004).
  • Spisek R , ChevallierP, MorineauN et al.: Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.Cancer Res.62(10) , 2861–2868 (2002).
  • Hasebe H , NagayamaH, SatoK et al.: Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients.Biomed. Pharmacother.54(6) , 291–298 (2000).
  • Royer PJ , BougrasG, EbsteinF et al.: Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.Exp. Hematol.36(3) , 329–339 (2008).
  • Merrick A , DiazRM, O‘DonnellD, SelbyP, VileR, MelcherA: Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy.Cancer Immunol. Immunother.57(6) , 897–906 (2008).
  • Felix NJ , AllenPM: Specificity of T-cell alloreactivity.Nat. Rev. Immunol.7(12) , 942–953 (2007).
  • Hus I , RolinskiJ, TabarkiewiczJ et al.: Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.Leukemia19(9) , 1621–1627 (2005).
  • Holtl L , RamonerR, Zelle-RieserC et al.: Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.Cancer Immunol. Immunother.54(7) , 663–670 (2005).
  • van der Bruggen P ., Van den Eynde BJ: Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol.18(1) , 98–104 (2006).
  • Greiner J , RinghofferM, TaniguchiM et al.: mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.Int. J. Cancer108(5) , 704–711 (2004).
  • Amoscato AA , PrenovitzDA, LotzeMT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells.J. Immunol.161(8) , 4023–4032 (1998).
  • Toes RE , OffringaR, BlomRJ, MeliefCJ, KastWM: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.Proc. Natl Acad. Sci. USA93(15) , 7855–7860 (1996).
  • Melief CJ , van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer8(5) , 351–360 (2008).
  • Van Driessche A , Van de Velde AL, Nijs G et al.: Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a Phase I dose-escalation clinical trial. Cytotherapy1–16 (2009).
  • Delluc S , TourneurL, FradeliziD et al.: DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.Cancer Immunol. Immunother.56(1) , 1–12 (2006).
  • Delluc S , TourneurL, MichalletAS et al.: Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.Haematologica90(8) , 1050–1062 (2005).
  • Delluc S , HachemP, RusakiewiczS et al.: Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.Cancer Immunol. Immunother.58(10) , 1669–1677 (2009).
  • Obeid M , TesniereA, GhiringhelliF et al.: Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat. Med.13(1) , 54–61 (2007).
  • Kono H , RockKL: How dying cells alert the immune system to danger.Nat. Rev. Immunol.8(4) , 279–289 (2008).
  • Panaretakis T , KeppO, BrockmeierU et al.: Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death.EMBO J.28(5) , 578–590 (2009).
  • Fujii S , FujimotoK, ShimizuK et al.: Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.Cancer Res.59(9) , 2150–2158 (1999).
  • Thomas-Kaskel AK , ves Portugal TG, Herchenbach D, Houet L, Veelken H, Finke J: Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4+ leukemia-reactive donor lymphocytes. Acta Haematol.117(4) , 226–235 (2007).
  • Spisek R , CharalambousA, MazumderA, VesoleDH, JagannathS, DhodapkarMV: Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.Blood109(11) , 4839–4845 (2007).
  • Johansson U , Walther-JallowL, Smed-SorensenA, SpetzAL: Triggering of dendritic cell responses after exposure to activated, but not resting, apoptotic PBMCs.J. Immunol.179(3) , 1711–1720 (2007).
  • Sen P , WalletMA, YiZ et al.: Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kB activation in dendritic cells.Blood.109(2) , 653–660 (2007).
  • Blander JM , MedzhitovR: On regulation of phagosome maturation and antigen presentation.Nat. Immunol.7(10) , 1029–1035 (2006).
  • Green DR , FergusonT, ZitvogelL, KroemerG: Immunogenic and tolerogenic cell death.Nat. Rev. Immunol.9(5) , 353–363 (2009).
  • Spisek R , DhodapkarMV: Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.Cell Cycle6(16) , 1962–1965 (2007).
  • Smits EL , PonsaertsP, Van de Velde AL et al.: Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia21(8) , 1691–1699 (2007).
  • Lane JD , AllanVJ, WoodmanPG: Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells.J. Cell Sci.118(Pt 17) , 4059–4071 (2005).
  • Fransen JH , HilbrandsLB, RubenJ et al.: Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17.Arthritis Rheum.60(8) , 2304–2313 (2009).
  • Iero M , ValentiR, HuberV et al.: Tumour-released exosomes and their implications in cancer immunity.Cell Death Differ.15(1) , 80–88 (2008).
  • Steinman RM , TurleyS, MellmanI, InabaK: The induction of tolerance by dendritic cells that have captured apoptotic cells.J. Exp. Med.191(3) , 411–416 (2000).
  • Sauter B , AlbertML, FranciscoL, LarssonM, SomersanS, BhardwajN: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.J. Exp. Med.191(3) , 423–434 (2000).
  • Rock KL , KonoH: The inflammatory response to cell death.Annu. Rev. Pathol.3 , 99–126 (2008).
  • Vakkila J , LotzeMT: Inflammation and necrosis promote tumour growth.Nat. Rev. Immunol.4(8) , 641–648 (2004).
  • Roskrow MA , DillooD, SuzukiN, ZhongW, RooneyCM, BrennerMK: Autoimmune disease induced by dendritic cell immunization against leukemia.Leuk. Res.23(6) , 549–557 (1999).
  • Schui DK , SinghL, SchneiderB, KnauA, HoelzerD, WeidmannE: Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts.Leuk. Res.26(4) , 383–389 (2002).
  • Galea-Lauri J , WellsJW, DarlingD, HarrisonP, FarzanehF: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of anti-tumor T-cell responses in dendritic cell-based cancer vaccination.Cancer Immunol. Immunother.53(11) , 963–977 (2004).
  • Qiu J , LiGW, SuiYF, SongHP, SiSY, GeW: Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo.World J. Gastroenterol.12(3) , 473–478 (2006).
  • Xing D , DeckerWK, LiS et al.: AML-loaded DC generate Th1-type cellular immune responses in vitro.Cytotherapy8(2) , 95–104 (2006).
  • Lee JJ , ParkMS, ParkJS et al.: Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens.J. Clin. Apher.21(3) , 188–194 (2006).
  • Lee JJ , KookH, ParkMS et al.: Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.J. Clin. Apher.19(2) , 66–70 (2004).
  • Hsu AK , KerrBM, JonesKL, LockRB, HartDN, RiceAM: RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.Biol. Blood Marrow Transplant12(8) , 855–867 (2006).
  • Jarnjak-Jankovic S , PettersenRD, Saeboe-LarssenS, WesenbergF, GaudernackG: Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia.BMC Cance.5 , 20–30 (2005).
  • Jarnjak-Jankovic S , HammerstadH, Saeboe-LarssenS, KvalheimG, GaudernackG: A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.BMC Cancer7 , 119 (2007).
  • Dissanayake SK , TueraN, Ostrand-RosenbergS: Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.J. Immunol.174(4) , 1811–1819 (2005).
  • Decker WK , XingD, LiS et al.: Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.Vaccine24(16) , 3203–3216 (2006).
  • Ji H , WangTL, ChenCH et al.: Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the anti-tumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.Hum. Gene Ther.10(17) , 2727–2740 (1999).
  • Banat GA , UsluogluN, HoeckM, IhlowK, HoppmannS, PralleH: Dendritic cells fused with core binding factor-β positive acute myeloid leukaemia blasT cells induce activation of cytotoxic lymphocytes.Br. J. Haematol.126(4) , 593–601 (2004).
  • Klammer M , WaterfallM, SamuelK, TurnerML, RoddiePH: Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.Br. J. Haematol.129(3) , 340–349 (2005).
  • Lei Z , ZhangGM, HongM, FengZH, HuangB: Fusion of dendritic cells and CD34+CD38- acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction.J. Immunother.32(4) , 408–414 (2009).
  • Weigel BJ , Panoskaltsis-MortariA, DiersM et al.: Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo anti-tumor protective responses.Exp. Hematol.34(10) , 1403–1412 (2006).
  • Galea-Lauri J , DarlingD, MuftiG, HarrisonP, FarzanehF: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.Cancer Immunol. Immunother.51(6) , 299–310 (2002).
  • Kotera Y , ShimizuK, MuleJJ: Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization.Cancer Res.61(22) , 8105–8109 (2001).
  • Larmonier N , MerinoD, NicolasA et al.: Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading.Apoptosis11(9) , 1513–1524 (2006).
  • Guy B : The perfect mix: recent progress in adjuvant research.Nat. Rev. Microbiol.5(7) , 505–517 (2007).
  • Amigorena S : Fc-γ receptors and cross-presentation in dendritic cells.J. Exp. Med.195(1) , F1–F3 (2002).
  • Franki SN , StewardKK, BettingDJ, KafiK, YamadaRE, TimmermanJM: Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B cell lymphoma in vivo.Blood111(3) , 1504–1511 (2007).
  • Castellino F , BoucherPE, EichelbergK et al.: Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways.J. Exp. Med.191(11) , 1957–1964 (2000).
  • Shi H , CaoT, ConnollyJE et al.: Hyperthermia enhances CTL cross-priming.J. Immunol.176(4) , 2134–2141 (2006).
  • Gavin AL , HoebeK, DuongB et al.: Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.Science314(5807) , 1936–1938 (2006).
  • Wilson NS , BehrensGM, LundieRJ et al.: Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity.Nat. Immunol.7(2) , 165–172 (2006).
  • Ten Brinke A , KarstenML, DiekerMC, ZwagingaJJ, Van Ham SM: The clinical grade maturation cocktail monophosphoryl lipid A plus IFN-γ generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine25(41) , 7145–7152 (2007).
  • Seya T , AkazawaT, TsujitaT, MatsumotoM: Role of Toll-like receptors in adjuvant-augmented immune therapies.Evid. Based Complement Alternat. Med.3(1) , 31–38 (2006).
  • Stary G , BangertC, AltrichterS, StrohalR, KoppT, StingleG: Dendritic cells with cytotoxic potential after Toll-like receptor 7/8-activation. Presented at: Dendritic Cells 9th International Conference. Edinburgh, UK, 16–20 September 2006.
  • Klinman DM : Immunotherapeutic uses of CpG oligodeoxynucleotides.Nat. Rev. Immunol.4(4) , 249–258 (2004).
  • Jarnicki AG , ConroyH, BreretonC et al.: Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.J. Immunol.180(6) , 3797–3806 (2008).
  • Li L , GiannopoulosK, ReinhardtP et al.: Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.Int. J. Oncol.28(4) , 855–861 (2006).
  • Westers TM , OssenkoppeleGJ, van de Loosdrecht AA: Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. Biomed. Pharmacother.61(6) , 306–314 (2007).
  • Oka Y , TsuboiA, TaguchiT et al.: Induction of WT1 (Wilms‘ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.Proc. Natl Acad. Sci. USA101(38) , 13885–13890 (2004).
  • Rezvani K , YongAS, MielkeS et al.: Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Blood111(1) , 236–242 (2007).
  • Gao L , BellantuonoI, ElsasserA et al.: Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1.Blood95(7) , 2198–2203 (2000).
  • Bellantuono I , GaoL, ParryS et al.: Two distinct HLA-A0201-presented epitopes of the Wilms‘ tumor antigen 1 can function as targets for leukemia-reactive CTL.Blood100(10) , 3835–3837 (2002).
  • Kitawaki T , KadowakiN, KondoT et al.: Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia.Am. J. Hematol.83(4) , 315–317 (2007).
  • Tacken PJ , deV, I, Torensma R, Figdor CG: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10) , 790–802 (2007).
  • Rusakiewicz S , MadrigalA, TraversP, DodiAI: BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.Cancer Immunol. Immunother.58(9) , 1449–1457 (2009).
  • Westers TM , HoutenbosI, SnoijsNC, van de Loosdrecht AA, Ossenkoppele GJ: Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia19(7) , 1270–1272 (2005).
  • Feller N , van der Pol MA, van SA et al.: MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia18(8) , 1380–1390 (2004).
  • Candoni A , TiribelliM, ToffolettiE et al.: Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.Eur. J. Haematol.82(1) , 61–68 (2009).
  • Xu W , CeleridadM, SankarS, WebbDR, BennettBL: CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet.Clin. Immunol.128(3) , 392–399 (2008).
  • Khong T , SharkeyJ, SpencerA: The effect of azacitidine on interleukin-6 signaling and nuclear factor-kB activation and its in vitro and in vivo activity against multiple myeloma.Haematologica93(6) , 860–869 (2008).
  • Magner WJ , KazimAL, StewartC et al.: Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.J. Immunol.165(12) , 7017–7024 (2000).
  • Moldenhauer A , FrankRC, Pinilla-IbarzJ et al.: Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.J. Leukoc. Biol.76(3) , 623–633 (2004).
  • Mullins DW , SheasleySL, ReamRM, BullockTN, FuYX, EngelhardVH: Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control.J. Exp. Med.198(7) , 1023–1034 (2003).
  • Fong L , BrockstedtD, BenikeC, WuL, EnglemanEG: Dendritic cells injected via different routes induce immunity in cancer patients.J. Immunol.166(6) , 4254–4259 (2001).
  • Butterfield LH , RibasA, DissetteVB et al.: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.Clin. Cancer Res.9(3) , 998–1008 (2003).
  • Krause P , BrucknerM, UermosiC, SingerE, GroettrupM, LeglerDF: Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells.Blood113(11) , 2451–2460 (2009).
  • de Vries I , LesterhuisWJ, ScharenborgNM et al.: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.Clin. Cancer Res.9(14) , 5091–5100 (2003).
  • von Bergwelt-Baildon MS , PopovA, SaricT et al.: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.Blood108(1) , 228–237 (2006).
  • Luft T , JeffordM, LuetjensP et al.: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.Blood100(4) , 1362–1372 (2002).
  • Muthuswamy R , UrbanJ, LeeJJ, ReinhartTA, BartlettD, KalinskiP: Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation.Cancer Res.68(14) , 5972–5978 (2008).
  • Dauer M , LamV, ArnoldH et al.: Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production.J. Immunol. Methods337(2) , 97–105 (2008).
  • Bedrosian I , MickR, XuS et al.: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.J. Clin. Oncol.21(20) , 3826–3835 (2003).
  • Verdijk P , AarntzenEH, LesterhuisWJ et al.: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.Clin. Cancer Res.15(7) , 2531–2540 (2009).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.